SIRS-Lab produces molecular diagnostic systems to identify life-threatening infections. The main objective is early and targeted antibiotic therapy of sepsis, the leading cause of death in hospitals.
In 1999, the first discussion for the creation of a company between Dr. Rußwurm and representatives of BioRegio e.V. started. Four month later, a business plan was submitted and SIRS-Lab GmbH was founded at the beginning of 2000. Along with Hans Peter Saluz and Dr. Rußwurm, Prof. Dr. Konrad Reinhart (Clinic for Anaesthesiology and Intensive Care Medicine, FSU) and Prof. Dr. Eberhard Straube (Institute for Medical Microbiology, FSU) were co-founders. After conclusion of the Venture Capital contracts, SIRS-Lab GmbH started its operative business in March 2001.SIRS-Lab wants to create value by the development of systems which facilitate and automate customer processes to improve productivity as measured against economic and resultsoriented standards. In doing so, its strategic initiatives are focussed on the expansion of its core business, efficient utilization of the biomedical testing continuum and investment in promising projects. For that purpose, SIRS-Lab GmbH has built an interdisciplinary team of applied researchers and clinicians specialised in the fields of infection research. SIRS-Lab established a strong networks: the company has close co-operations, with, among others, the Clinic for Anaesthesiology and Intensive Care Medicine of the FSU Jena.